Date: 2016-05-18
Type of information: Initiation of patient enrollment
phase: 1
Announcement: initiation of patient enrollment
Company: Herantis Pharma (Finland)
Product: Lymfactin®
Action
mechanism: gene therapy. Lymfactin® is an adenovirus-based gene therapy expressing the growth factor VEGF-C specific to the development of lymphatic vessels. Based on preclinical studies it is expected to trigger the growth of new functional lymphatic vasculature in the damaged area and thus repair the underlying cause of lymphedema. Lymfactin®, patented by Herantis, is based on scientific research of academy professor Kari Alitalo and his research group at the University of Helsinki. Herantis also holds patents for a combination therapy, which may expand the use of Lymfactin® in primary lymphedema.
Disease: breast cancer associated secondary lymphedema
Therapeutic area: Cancer - Oncology
Country: Finland
Trial details:
Latest
news: * On May 18, 2016, Herantis Pharma has started patient recruitment for its clinical study with Lymfactin® for the treatment of breast cancer associated secondary lymphedema. While the primary endpoint of the study is to assess the safety and tolerability of Lymfactin® the study will also assess the preliminary efficacy of the treatment. The Phase 1 clinical study is now recruiting patients with breast cancer associated lymphedema at the Helsinki University Central Hospital in Finland. Two further study sites in Finland are planned for opening later this year. The study intends to recruit at most 18 patients, and recruitment is expected to be completed in 2017.
